Clinical Report: The New Path to ADCs

Overview

Recent discussions at the World ADC London panel highlighted the need for antibody-drug conjugates (ADCs) to prioritize patient tolerability alongside efficacy. Experts emphasized that improving the quality of life for patients is essential, as adverse events often lead to therapy abandonment.

Background

Antibody-drug conjugates (ADCs) represent a promising therapeutic strategy in oncology, combining the specificity of antibodies with the potency of cytotoxic drugs. However, the historical focus on potency over tolerability has raised concerns about the real-world impact of these therapies on patients' daily lives. Addressing tolerability is crucial for enhancing patient adherence and overall treatment success.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Current ADC development must prioritize patient tolerability to improve quality of life.
• Adverse events, even at manageable grades, can significantly impact daily activities and lead to therapy abandonment.
• There is a need for new mechanisms of tolerability rather than relying on existing toxic payloads.
• More selective payloads are anticipated to define the next generation of ADCs.
• Repurposing 'fallen angel' small molecules could enhance targeted payload delivery in ADCs.

Clinical Implications

Healthcare professionals should consider the tolerability of ADCs as a critical factor in treatment planning. By focusing on therapies that minimize adverse events, clinicians can improve patient adherence and overall treatment outcomes.

Conclusion

The shift towards prioritizing patient quality of life in ADC development represents a significant evolution in oncology. Future advancements must balance efficacy with tolerability to ensure sustainable patient care.

References

1. Dana-Farber, 2025 SABCS Highlights: Advances in ADC's for Advanced Breast Cancer
2. Dana-Farber, Paolo Tarantino, MD, on ADCs
3. European Radiology, Establishment of a breast apparent diffusion coefficient classification system (ADC-B)
4. The ASCO Post, ADC Improves Outcomes for Patients With Advanced TNBC Ineligible for Immunotherapy
5. PubMed, Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights
6. The ASCO Post, T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy
7. The ASCO Post, Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd
8. Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights - PubMed
9. T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy - The ASCO Post
10. Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd - The ASCO Post